Diabetes Mellitus and Other Predictors for the Successful Treatment of Metastatic Colorectal Cancer: A Retrospective Study
<i>Background and Objectives</i>: In the last decades there has been an increasing body of research identifying the positive correlation between diabetes mellitus (DM) and solid malignancies, moreover, having shown DM as an independent risk factor for colorectal cancer (CRC). The aim of...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Medicina |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1648-9144/58/7/872 |
| _version_ | 1827628074452123648 |
|---|---|
| author | Deiana Roman Sorin Saftescu Bogdan Timar Vlad Avram Adina Braha Șerban Negru Andrei Bercea Monica Serbulescu Dorel Popovici Romulus Timar |
| author_facet | Deiana Roman Sorin Saftescu Bogdan Timar Vlad Avram Adina Braha Șerban Negru Andrei Bercea Monica Serbulescu Dorel Popovici Romulus Timar |
| author_sort | Deiana Roman |
| collection | DOAJ |
| description | <i>Background and Objectives</i>: In the last decades there has been an increasing body of research identifying the positive correlation between diabetes mellitus (DM) and solid malignancies, moreover, having shown DM as an independent risk factor for colorectal cancer (CRC). The aim of the present study was to assess the impact of DM on metastatic CRC (mCRC), and to identify possible predictive factors in the successful treatment of mCRC. <i>Materials and Methods</i>: 468 patients with mCRC were included in this retrospective, observational study. A total of 8669 oncological treatment cycles related to 988 distinct chemotherapy lines were analyzed. Data regarding lines of treatment and blood panel values were obtained from the Oncohelp Hospital database. <i>Results</i>: The presence of DM in male patients >70 years was a negative predictor (RR = 1.66 and a <i>p</i> = 0.05). DM seemed to have a detrimental effect in patients whose treatment included bevacizumab (median time to treatment failure -TTF- 94 days for DM+ cases compared to 114 days for DM-patients, <i>p</i> = 0.07). Analysis of treatments including bevacizumab based on DM status revealed lower values of mean TTF in DM+ female patients versus DM-(81.08 days versus 193.09 days, <i>p</i> < 0.001). It was also observed that DM+ patients had a higher mean TTF when undergoing anti-EGFR (epidermal growth factor) therapy (median TTF 143 days for DM+ patients versus 97.5 days for those without DM, <i>p</i> = 0.06). <i>Conclusions</i>: The favorable predictive factors identified were the inclusion of antiangiogenic agents, a higher hemoglobin value, a higher lymphocyte count, the inclusion of anti-EGFR treatment for DM+ patients, a higher creatinine, and a higher lymphocyte count in treatment lines that included anti-EGFR treatment. Unfavorable predictive factors were represented by the presence of DM in female patients undergoing antiangiogenic treatment, neutropenia in male patients, the association of oxaliplatin and antiangiogenic agents, and a higher monocyte count in the aforementioned treatment lines. |
| first_indexed | 2024-03-09T13:25:41Z |
| format | Article |
| id | doaj.art-cfed9bc66c134ec69994e62e30b85d60 |
| institution | Directory Open Access Journal |
| issn | 1010-660X 1648-9144 |
| language | English |
| last_indexed | 2024-03-09T13:25:41Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Medicina |
| spelling | doaj.art-cfed9bc66c134ec69994e62e30b85d602023-11-30T21:24:56ZengMDPI AGMedicina1010-660X1648-91442022-06-0158787210.3390/medicina58070872Diabetes Mellitus and Other Predictors for the Successful Treatment of Metastatic Colorectal Cancer: A Retrospective StudyDeiana Roman0Sorin Saftescu1Bogdan Timar2Vlad Avram3Adina Braha4Șerban Negru5Andrei Bercea6Monica Serbulescu7Dorel Popovici8Romulus Timar9Second Department of Internal Medicine, “Victor Babeș” University of Medicine and Pharmacy, 300041 Timisoara, RomaniaDepartment of Oncology, “Victor Babeș” University of Medicine and Pharmacy, 300041 Timisoara, RomaniaSecond Department of Internal Medicine, “Victor Babeș” University of Medicine and Pharmacy, 300041 Timisoara, RomaniaSecond Department of Internal Medicine, “Victor Babeș” University of Medicine and Pharmacy, 300041 Timisoara, RomaniaSecond Department of Internal Medicine, “Victor Babeș” University of Medicine and Pharmacy, 300041 Timisoara, RomaniaDepartment of Oncology, “Victor Babeș” University of Medicine and Pharmacy, 300041 Timisoara, RomaniaOncoHelp Hospital, 300239 Timisoara, RomaniaOncoHelp Hospital, 300239 Timisoara, RomaniaDepartment of Oncology, “Victor Babeș” University of Medicine and Pharmacy, 300041 Timisoara, RomaniaSecond Department of Internal Medicine, “Victor Babeș” University of Medicine and Pharmacy, 300041 Timisoara, Romania<i>Background and Objectives</i>: In the last decades there has been an increasing body of research identifying the positive correlation between diabetes mellitus (DM) and solid malignancies, moreover, having shown DM as an independent risk factor for colorectal cancer (CRC). The aim of the present study was to assess the impact of DM on metastatic CRC (mCRC), and to identify possible predictive factors in the successful treatment of mCRC. <i>Materials and Methods</i>: 468 patients with mCRC were included in this retrospective, observational study. A total of 8669 oncological treatment cycles related to 988 distinct chemotherapy lines were analyzed. Data regarding lines of treatment and blood panel values were obtained from the Oncohelp Hospital database. <i>Results</i>: The presence of DM in male patients >70 years was a negative predictor (RR = 1.66 and a <i>p</i> = 0.05). DM seemed to have a detrimental effect in patients whose treatment included bevacizumab (median time to treatment failure -TTF- 94 days for DM+ cases compared to 114 days for DM-patients, <i>p</i> = 0.07). Analysis of treatments including bevacizumab based on DM status revealed lower values of mean TTF in DM+ female patients versus DM-(81.08 days versus 193.09 days, <i>p</i> < 0.001). It was also observed that DM+ patients had a higher mean TTF when undergoing anti-EGFR (epidermal growth factor) therapy (median TTF 143 days for DM+ patients versus 97.5 days for those without DM, <i>p</i> = 0.06). <i>Conclusions</i>: The favorable predictive factors identified were the inclusion of antiangiogenic agents, a higher hemoglobin value, a higher lymphocyte count, the inclusion of anti-EGFR treatment for DM+ patients, a higher creatinine, and a higher lymphocyte count in treatment lines that included anti-EGFR treatment. Unfavorable predictive factors were represented by the presence of DM in female patients undergoing antiangiogenic treatment, neutropenia in male patients, the association of oxaliplatin and antiangiogenic agents, and a higher monocyte count in the aforementioned treatment lines.https://www.mdpi.com/1648-9144/58/7/872diabetes mellituscolorectal cancermetastatic cancerchemotherapy |
| spellingShingle | Deiana Roman Sorin Saftescu Bogdan Timar Vlad Avram Adina Braha Șerban Negru Andrei Bercea Monica Serbulescu Dorel Popovici Romulus Timar Diabetes Mellitus and Other Predictors for the Successful Treatment of Metastatic Colorectal Cancer: A Retrospective Study Medicina diabetes mellitus colorectal cancer metastatic cancer chemotherapy |
| title | Diabetes Mellitus and Other Predictors for the Successful Treatment of Metastatic Colorectal Cancer: A Retrospective Study |
| title_full | Diabetes Mellitus and Other Predictors for the Successful Treatment of Metastatic Colorectal Cancer: A Retrospective Study |
| title_fullStr | Diabetes Mellitus and Other Predictors for the Successful Treatment of Metastatic Colorectal Cancer: A Retrospective Study |
| title_full_unstemmed | Diabetes Mellitus and Other Predictors for the Successful Treatment of Metastatic Colorectal Cancer: A Retrospective Study |
| title_short | Diabetes Mellitus and Other Predictors for the Successful Treatment of Metastatic Colorectal Cancer: A Retrospective Study |
| title_sort | diabetes mellitus and other predictors for the successful treatment of metastatic colorectal cancer a retrospective study |
| topic | diabetes mellitus colorectal cancer metastatic cancer chemotherapy |
| url | https://www.mdpi.com/1648-9144/58/7/872 |
| work_keys_str_mv | AT deianaroman diabetesmellitusandotherpredictorsforthesuccessfultreatmentofmetastaticcolorectalcanceraretrospectivestudy AT sorinsaftescu diabetesmellitusandotherpredictorsforthesuccessfultreatmentofmetastaticcolorectalcanceraretrospectivestudy AT bogdantimar diabetesmellitusandotherpredictorsforthesuccessfultreatmentofmetastaticcolorectalcanceraretrospectivestudy AT vladavram diabetesmellitusandotherpredictorsforthesuccessfultreatmentofmetastaticcolorectalcanceraretrospectivestudy AT adinabraha diabetesmellitusandotherpredictorsforthesuccessfultreatmentofmetastaticcolorectalcanceraretrospectivestudy AT serbannegru diabetesmellitusandotherpredictorsforthesuccessfultreatmentofmetastaticcolorectalcanceraretrospectivestudy AT andreibercea diabetesmellitusandotherpredictorsforthesuccessfultreatmentofmetastaticcolorectalcanceraretrospectivestudy AT monicaserbulescu diabetesmellitusandotherpredictorsforthesuccessfultreatmentofmetastaticcolorectalcanceraretrospectivestudy AT dorelpopovici diabetesmellitusandotherpredictorsforthesuccessfultreatmentofmetastaticcolorectalcanceraretrospectivestudy AT romulustimar diabetesmellitusandotherpredictorsforthesuccessfultreatmentofmetastaticcolorectalcanceraretrospectivestudy |